fondaparinux trial summary

Acute coronary syndrome

All type of patients: 2 trials - PENTUA - OASIS 5

No demonstrated result

Acute myocardial infarction

All type of patients: 1 trials - MICHELANGELO OASIS-6

No demonstrated result

suggested reinfarction by 32% (not demonstrated)

suggested Deaths or MI by 13% (not demonstrated)

suggested death at 30 days by 13% (not demonstrated)

Percutaneous coronary intervention

All type of patients: 1 trials - SWITCH III

No demonstrated result

Pulmonary embolism

All type of patients: 1 trials - MATISSE PE

No demonstrated result

Superficial thrombophlebitis

Superficial thrombophlebitis of the leg : 1 trials - CALISTO

No demonstrated result

suggested Deep vein thrombosis by 83% (not demonstrated)

suggested Venous thromboembolism by 85% (not demonstrated)

Thrombosis prevention

Abdominal surgery: 3 trials - APOLLO (Turpie) - PEGASUS - NCT00333021

No demonstrated result

suggested Deep vein thrombosis by 69% (not demonstrated)

suggested Venous thromboembolism by 69% (not demonstrated)

suggested Major bleeding by 924% (not demonstrated)

See more clinical conditions

All type of patients: 13 trials - PENTAMAKS (Bauer) - PENTHIFRA (Eriksson) - PENTATHLON (Turpie) - EPHESUS (Lassen) - Turpie - APOLLO (Turpie) - PEGASUS - PROTECT (fundaparinux) - NCT00333021 - NCT00320398 - L8541 - L8635 - DRI4757

No demonstrated result

suggested Deep vein thrombosis by 48% (not demonstrated)

suggested Venous thromboembolism by 46% (not demonstrated)

suggested proximal DVT by 50% (not demonstrated)

suggested Major bleeding by 39% (not demonstrated)

No demonstrated result

suggested Deep vein thrombosis by 69% (not demonstrated)

suggested Venous thromboembolism by 69% (not demonstrated)

suggested Major bleeding by 924% (not demonstrated)

Elective hip replacement: 3 trials - PENTATHLON (Turpie) - EPHESUS (Lassen) - NCT00320398

No demonstrated result

suggested Deep vein thrombosis by 45% (not demonstrated)

suggested Symptomatic deep-vein thrombosis by 479% (not demonstrated)

suggested Venous thromboembolism by 43% (not demonstrated)

suggested Major bleeding by 59% (not demonstrated)

Elective major knee surgery : 2 trials - PENTAMAKS (Bauer) - L8635

No demonstrated result

suggested Deep vein thrombosis by 54% (not demonstrated)

suggested Venous thromboembolism by 55% (not demonstrated)

suggested Major bleeding by 535% (not demonstrated)

Hip Fracture: 1 trials - PENTHIFRA (Eriksson)

No demonstrated result

suggested Deep vein thrombosis by 58% (not demonstrated)

suggested Venous thromboembolism by 56% (not demonstrated)

suggested proximal DVT by 79% (not demonstrated)

Medical patients: 2 trials - ARTEMIS (Cohen) - BRiEF

No demonstrated result

Orthopedic surgery: 9 trials - PENTAMAKS (Bauer) - PENTHIFRA (Eriksson) - PENTATHLON (Turpie) - EPHESUS (Lassen) - Turpie - NCT00320398 - L8541 - L8635 - DRI4757

No demonstrated result

suggested Deep vein thrombosis by 52% (not demonstrated)

suggested Venous thromboembolism by 50% (not demonstrated)

suggested proximal DVT by 54% (not demonstrated)

suggested Major bleeding by 38% (not demonstrated)

No demonstrated result

Patients with immobilization of the lower extremities: 2 trials - PROTECT (fundaparinux) - FONDACAST

No demonstrated result

Venous thrombosis

All type of patients: 2 trials - MATISSE - MATISSE PE

No demonstrated result

Fondaparinux antithrombotics

Arixtra - Quixidar

Acute coronary syndrome

Acute myocardial infarction

Percutaneous coronary intervention

Pulmonary embolism

Superficial thrombophlebitis

Thrombosis prevention

Venous thrombosis